Altimmune (ALT) Earnings Date, Estimates & Call Transcripts $4.08 +0.03 (+0.74%) Closing price 04:00 PM EasternExtended Trading$4.10 +0.02 (+0.49%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Altimmune Earnings Summary Altimmune announced Q1 2025 earnings on May 13, 2025, reporting an EPS of -$0.26, which topped the consensus estimate of -$0.35 by $0.09. Quarterly revenue was reported to be $0.01 million, above the consensus estimate of $0 million. With a trailing EPS of -$1.26, Altimmune's earnings are expected to grow next year, from ($1.35) to ($0.96) per share. Upcoming Q2 Earnings DateAug. 6Before Market OpensEstimatedConsensus EPS (May. 13) -$0.35 Actual EPS (May. 13) -$0.26 Beat By $0.09 Actual Revenue (May. 13) $0.01MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)ALT Upcoming EarningsAltimmune's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get Altimmune Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Altimmune and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataALT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Altimmune Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.41-$0.33-$0.37Q2 20253-$0.33-$0.26-$0.30Q3 20253-$0.34-$0.32-$0.33Q4 20253-$0.40-$0.32-$0.36 FY 2025 11 -$1.48 -$1.23 -$1.36 Q1 20262-$0.37-$0.37-$0.37Q2 20262-$0.37-$0.34-$0.36Q3 20262-$0.37-$0.34-$0.36Q4 20262-$0.41-$0.33-$0.37 Altimmune Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------5/13/2025Q1 2025-$0.35-$0.26+$0.09-$0.26$0.00M$0.01M2/27/2025Q4 2024-$0.34-$0.33+$0.01-$0.33$0.00M$0.01M11/12/2024Q3 2024-$0.35-$0.32+$0.03-$0.32-$0.01M8/8/2024Q2 2024-$0.34-$0.35 -$0.01-$0.35-$0.01M5/9/2024Q1 2024-$0.36-$0.34+$0.02-$0.34-$0.01M3/27/2024Q4 2023-$0.35-$0.33+$0.02-$0.12-$0.04M11/7/2023Q3 2023-$0.40-$0.39+$0.01-$0.39-$0.36M8/10/2023Q2 2023-$0.44-$0.32+$0.12-$0.32-$0.01M Altimmune Earnings - Frequently Asked Questions When is Altimmune's earnings date? Altimmune has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on ALT's earnings history. Did Altimmune beat their earnings estimates last quarter? In the previous quarter, Altimmune (NASDAQ:ALT) reported ($0.26) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.35) by $0.09. Learn more on analysts' earnings estimate vs. ALT's actual earnings. How can I listen to Altimmune's earnings conference call? The conference call for Altimmune's latest earnings report can be listened to online. Listen to Conference Call How can I read Altimmune's conference call transcript? The conference call transcript for Altimmune's latest earnings report can be read online. Read Transcript How much revenue does Altimmune generate each year? Altimmune (NASDAQ:ALT) has a recorded annual revenue of $20,000.00. How much profit does Altimmune generate each year? Altimmune (NASDAQ:ALT) has a recorded net income of -$95.06 million. ALT has generated -$1.26 earnings per share over the last four quarters. What is Altimmune's EPS forecast for next year? Altimmune's earnings are expected to grow from ($1.35) per share to ($0.96) per share in the next year. More Earnings Resources from MarketBeat Related Companies HROW Earnings Results PAHC Earnings Results ABCL Earnings Results COGT Earnings Results PHVS Earnings Results NTLA Earnings Results CVAC Earnings Results AUPH Earnings Results WVE Earnings Results CALT Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report This page (NASDAQ:ALT) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredMiss This Window And You Miss EverythingThere’s a moment in every crypto cycle when everything just clicks — and that moment is now. This is the ph...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
